January 23, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, all ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

New York, New York-- (Newsfile Corp. - January 19, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...

Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

PHILADELPHIA - Context Therapeutics Inc. (NASDAQ:CNTX), a company focused on developing treatments for solid tumors, announced the addition of Karen Smith, MD, PhD, MBA, LLM and... Context ...

In a challenging economic environment, ZURA's stock has hit a 52-week low, dropping to $1.75. According to InvestingPro ...